Fahad Quhal1,2, Benjamin Pradere1,3, Reza Sari Motlagh1, Keiichiro Mori1,4, Ekaterina Laukhtina1,5, Abdulmajeed Aydh1,6, Hadi Mostafaei1,7, Ivan Lysenko1, Victor M Schuettfort1,8, Franziska Stolzenbach9, Carlotta Palumbo9, Axel Heidenreich10, Alberto Briganti11, Pierre I Karakiewicz9, Piotr Chlosta12, Shahrokh F Shariat13,5,14,15,16,17,18,19. 1. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. 2. Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia. 3. Department of Urology, University Hospital of Tours, Tours, France. 4. School of Medicine, Department of Urology, The Jikei University, Tokyo, Japan. 5. Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. 6. King Faisal Medical City, Abha, Saudi Arabia. 7. Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. 8. Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 9. Unit of Cancer Prognostics and Health Outcomes, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada. 10. Department of Urology, University Hospital Cologne, Cologne, Germany. 11. Unit of Urology, Division of Oncology, URI, IRCCS San Raffaele Hospital, Milan, Italy. 12. Department of Urology, Jagiellonian University Medical College, Kraków, Poland. 13. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria - shahrokh.shariat@meduniwien.ac.at. 14. Department of Urology, Weill Cornell Medical College, New York, NY, USA. 15. Department of Urology, University of Texas Southwestern, Dallas, TX, USA. 16. Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. 17. Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. 18. European Association of Urology Research Foundation, Arnhem, the Netherlands. 19. Karl Landsteiner Institute, Vienna, Austria.
Abstract
BACKGROUND: Serum albumin-to-globulin ratio (AGR) has been shown to be associated with poor prognosis in different malignancies. In this study we aimed to evaluate the predictive value of preoperative AGR for oncological outcomes in patients with radiation recurrent prostate cancer (PCa) treated with salvage radical prostatectomy (SRP). METHODS: A retrospective review of 214 consecutive patients with radiation recurrent PCa who underwent SRP at five referral centers. Levels of albumin and globulin were obtained before SRP and used to calculate the preoperative AGR level. The optimal cut off value of preoperative AGR was 1.4. Univariable and multivariable Cox regression analyses were performed. RESULTS: Overall 89 (41.6%) patients had a low preoperative AGR. Low serum AGR was associated with biochemical recurrence (BCR) in univariable Cox regression analysis (HR 1.60, 95%CI 1.06-2.43, P=0.026). When adjusted for the effects of established preoperative and postoperative clinicopathologic confounders in different multivariable Cox regression models, this association did not retain its statistical significance. Moreover, preoperative AGR was not associated with metastasis free survival (P=0.21), overall survival (P=0.91) or cancer specific survival (P=0.61). CONCLUSIONS: In patients with radiation recurrent PCa undergoing SRP, low preoperative AGR was associated with the risk of BCR only in univariable analysis. There was no association with metastasis or survival outcomes. Further studies are needed to evaluate this biomarker in the setting of primary PCa and to identify the patients most likely to benefit from a local therapy.
BACKGROUND: Serum albumin-to-globulin ratio (AGR) has been shown to be associated with poor prognosis in different malignancies. In this study we aimed to evaluate the predictive value of preoperative AGR for oncological outcomes in patients with radiation recurrent prostate cancer (PCa) treated with salvage radical prostatectomy (SRP). METHODS: A retrospective review of 214 consecutive patients with radiation recurrent PCa who underwent SRP at five referral centers. Levels of albumin and globulin were obtained before SRP and used to calculate the preoperative AGR level. The optimal cut off value of preoperative AGR was 1.4. Univariable and multivariable Cox regression analyses were performed. RESULTS: Overall 89 (41.6%) patients had a low preoperative AGR. Low serum AGR was associated with biochemical recurrence (BCR) in univariable Cox regression analysis (HR 1.60, 95%CI 1.06-2.43, P=0.026). When adjusted for the effects of established preoperative and postoperative clinicopathologic confounders in different multivariable Cox regression models, this association did not retain its statistical significance. Moreover, preoperative AGR was not associated with metastasis free survival (P=0.21), overall survival (P=0.91) or cancer specific survival (P=0.61). CONCLUSIONS: In patients with radiation recurrent PCa undergoing SRP, low preoperative AGR was associated with the risk of BCR only in univariable analysis. There was no association with metastasis or survival outcomes. Further studies are needed to evaluate this biomarker in the setting of primary PCa and to identify the patients most likely to benefit from a local therapy.
Authors: Stefano Salciccia; Marco Frisenda; Giulio Bevilacqua; Pietro Viscuso; Paolo Casale; Ettore De Berardinis; Giovanni Battista Di Pierro; Susanna Cattarino; Gloria Giorgino; Davide Rosati; Francesco Del Giudice; Alessandro Sciarra; Gianna Mariotti; Alessandro Gentilucci Journal: Int J Mol Sci Date: 2022-09-29 Impact factor: 6.208
Authors: Fahad Quhal; Pawel Rajwa; Keiichiro Mori; Ekaterina Laukhtina; Nico C Grossmann; Victor M Schuettfort; Frederik König; Abdulmajeed Aydh; Reza S Motlagh; Satoshi Katayama; Hadi Mostafai; Benjamin Pradere; Giancarlo Marra; Paolo Gontero; Romain Mathieu; Pierre I Karakiewicz; Alberto Briganti; Shahrokh F Shariat; Axel Heidenreich Journal: Prostate Date: 2021-05-31 Impact factor: 4.104
Authors: Pawel Rajwa; Victor M Schuettfort; Fahad Quhal; Keiichiro Mori; Satoshi Katayama; Ekaterina Laukhtina; Benjamin Pradere; Reza Sari Motlagh; Hadi Mostafaei; Nico C Grossmann; Andreas Aulitzky; Andrzej Paradysz; Pierre I Karakiewicz; Harun Fajkovic; Kristin Zimmermann; Axel Heidenreich; Paolo Gontero; Shahrokh F Shariat Journal: World J Urol Date: 2021-05-17 Impact factor: 4.226